Metabolic memory for vascular disease in diabetes

Diabetes Technology and Therapeutics

Volumn 14, Issue SUPPL. 1, 2012, Pages

  Aschner, Pablo J ^a   Ruiz, Alvaro J ^a  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATENOLOL; CAPTOPRIL; CASPASE 3; GLICLAZIDE; GLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN A1C; HISTONE METHYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; PIOGLITAZONE; PLACEBO; PROTEIN KINASE C; SIRTUIN 1; SULFONYLUREA DERIVATIVE; SUPEROXIDE; TYROSINE;

APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL NUCLEUS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIET RESTRICTION; ENZYME ACTIVATION; ENZYME INHIBITION; EPIGENETICS; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; METABOLIC REGULATION; MITOCHONDRION; NITROSYLATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; TREATMENT OUTCOME; UNITED KINGDOM;

ANIMALS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOGS; EPIGENESIS, GENETIC; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; NF-KAPPA B; OXIDATIVE STRESS; PROTEIN KINASE C; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84861913103     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0012     Document Type: Article

References (36)

1. Engerman RL, Kern TS: Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987; 36:808-812.
2. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986.
3. The Diabetes Control and Complications Trial Research Group/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes. Four years after a trial of intensive therapy. N Engl J Med 2000;342:381-389.
4. The Diabetes Control and Complications Trial Research Group/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
5. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
6. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
7. Holman RR, Paul SK, Bethel A, Matthews, Neil AW: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
8. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving H-H, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383-393.
9. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591.
10. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-713. Erratum in BMJ 1999;318:29.
11. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR: Long-Term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008;359:1565-1576.
12. Murray P, Chune GW, Raghavan VA: Legacy effects from DCCT and UKPDS: What they mean and implications for future diabetes trials. Curr Atheroscler Rep 2010;12: 432-439.
13. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH, Messerli FH, Oparil S, Schork MA: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354: 1685-1697.
14. Harrap SB, Van Der Merwe WM, Griffin SA, Macpherson F, Lever AF: Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-Term. Hypertension 1990;16:603-614.
15. Volpe M, Cosentino F, Tocci G, Palano F, Paneni F: Antihypertensive therapy in diabetes: The legacy effect and RAAS blockade. Curr Hypertens Rep 2011;13:318-324.
16. Brownlee M: The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005;54:1615-1625.
17. Baker RG, Hayden MS, Ghosh S: NF-jB, inflammation, and metabolic disease. Cell Metab 2011;13:11-22.
18. Kowluru RA, Chakrabarti S, Chen S: Re-institution of good metabolic control in diabetic rats and activation of caspase-3 and nuclear transcriptional factor (NF-kappa B) in the retina. Acta Diabetol 2004;41:194-199.
19. Kowluru RA, Kanwar M, Kennedy A: Metabolic memory phenomenon and accumulation of peroxynitrite in retinal capillaries. Exp Diabetes Res 2007;2007:21976.
20. Kowluru RA: Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 2003;52:818-823.
21. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM; DCCT Skin Collagen Ancillary Study Group: Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes. Diabetes 2005;54:3103-3111.
22. Ceriello A, Ihnat MA, Thorpe JE: The metabolic memory'': Is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab 2009;94: 410-415.
23. Siebel AL, Fernandez AZ, El-Osta A: Glycemic memory associated epigenetic changes. Biochem Pharmacol 2010;80: 1853-1859.
24. Villeneuve LM, Reddy MA, Lanting LL, Meng L, Natarajan R: Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Nat Acad Sci U S A 2008; 105:9047-9052.
25. Villeneuve LM, Reddy MA, Natarajan R: Epigenetics: Geciphering its role in diabetes and its chronic complications. Clin Exp Pharmacol Physiol 2011;38:451-459.
26. Chan P-S, Kanwar M, Kowluru RA: Resistance of retinal inflammatory mediators to suppress after re-institution of good glycemic control: Novel mechanism for metabolic memory. J Diabetes Complications 2010;24:55-63.
27. Zhong Q, Kowluru RA: Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes 2011;60:1304-1313.
28. Syreeni A, El-Osta A, Forsblom C, Sandholm N, Parkkonen M, Tarnow L, Parving H-H, McKnight AJ, Maxwell A, Cooper ME, Groop P-H; FinnDiane Study: Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes. Diabetes 2011;60:3073-3080.
29. Ceriello A, Kumar S, Piconi L, Esposito K, Giugliano D: Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 2007;30:649-654.
30. Zheng Z, Chen H, Li J, Li T, Zheng B, Zheng Y, Jin H, He Y, Gu Q, Xu X: Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 2012;61:217-228.
31. LeRoithD, Fonseca V, Vinik A: Metabolic memory in diabetes-focus on insulin. Diabetes Metab Res Rev 2005;21: 85-90.
32. Yessoufou A, Moutairou K: Maternal diabetes in pregnancy: Early and long-Term outcomes on the offspring and the concept of metabolic memory.'' Exp Diabetes Res 2011; 2011:218598.
33. Lind M, Odén A, Fahlén M, Eliasson B: The shape of the metabolic memory of HbA1c: Re-analysing the DCCT with respect to time-dependent effects. Diabetologia 2010;53: 1093-1098.
34. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, Hämä läinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle TT, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group: Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: Follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-1679.
35. Diabetes Prevention Program Research Group: 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374: 1677-1686.
36. Li G, Zhang P, Wang J, Gregg E, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Bennett P: The long-Term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow-up study. Lancet 2008;371:1783-1789.